Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (Q35993027)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (English)

1 reference

Europe PubMed Central

11 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David A. Isenberg

9

object named as

David A Isenberg

1 reference

Europe PubMed Central

11 August 2017

Caroline Gordon

8

object named as

Caroline Gordon

1 reference

Europe PubMed Central

11 August 2017

1

object named as

Joan T Merrill

1 reference

Europe PubMed Central

11 August 2017

7

object named as

Tammy O Utset

1 reference

Europe PubMed Central

11 August 2017

author name string

C Michael Neuwelt

2

1 reference

Europe PubMed Central

11 August 2017

Daniel J Wallace

3

1 reference

Europe PubMed Central

11 August 2017

Joseph C Shanahan

4

1 reference

Europe PubMed Central

11 August 2017

Kevin M Latinis

5

1 reference

Europe PubMed Central

11 August 2017

James C Oates

6

1 reference

Europe PubMed Central

11 August 2017

Hsin-Ju Hsieh

10

1 reference

Europe PubMed Central

11 August 2017

David Zhang

11

1 reference

Europe PubMed Central

11 August 2017

Paul G Brunetta

12

1 reference

Europe PubMed Central

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2010

1 reference

Europe PubMed Central

11 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

11 August 2017

62

1 reference

Europe PubMed Central

11 August 2017

222-233

1 reference

Europe PubMed Central

11 August 2017

1

1 reference

Europe PubMed Central

11 August 2017

B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Effects of rituximab on resistant SLE disease including lung involvement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Assessment of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Dysfunctional B cells in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Diagnosis of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Pathogenesis of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

The role of B cells in lpr/lpr-induced autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

2 October 2017

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

11 July 2018

Systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Accrual of organ damage over time in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

23 September 2018

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

14 November 2018

The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4548300

14 November 2018

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

THE OCCURRENCE, NATURE AND DISTRIBUTION OF FLARES IN A COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RHEUMATOLOGICAL VIEW

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depletion of B cells in murine lupus: efficacy and resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition and treatment of lupus flares measured by the BILAG index

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutropenia in patients treated with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/20039413

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.27233

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35993027&oldid=2108093561"